ページの先頭です
HOME > Past Issue List > Issue List > Abstract
言語を選択(Language)
日本語(Japanese)English

Abstract

Vol.70 No.5 September 2022

Vancomycin removal ratio in patients on hemodialysis

Yuichi Kumaki1), Hideki Araoka2), Hiromi Tamura1), Masahiro Hayashi1), Naoki Sawa3) and Tadaaki Ito1)

1)Department of Pharmacy, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, Japan
2)Department of Infectious Diseases, Toranomon Hospital
3)Department of Nephrology Center, Toranomon Hospital

Abstract

The aim of this study was to determine the vancomycin (VCM) removal ratio in patients on hemodialysis (HD). Data of 19 patients (14 men, 5 women) on HD who were treated with VCM between October 2010 and September 2011 at Toranomon Hospital (Tokyo, Japan) were retrospectively evaluated. The median age was 67.6 (range, 43-87) years. The HD conditions were as follows: membrane area, 1.39 m2; blood and dialysate flow rate, 168.9 mL/min; and dialysis time, 3.7 h. The VCM removal ratio was defined as follows: VCM removal ratio (%) = [(Pre-HD serum concentration)-(4 h post-HD serum concentration)]/(Pre-HD serum concentration)×100. In the 19 patients, the mean VCM removal ratio was 22.9%±8.2% (range, 8.8-42.6%). The ratio was 21.6%±7.2% (range, 8.8-32.7%) in the 16 patients treated with a type IV dialyzer (β2-microglobulin clearance, 50-70 mL/min) classified in Japan, and 29.7%±11.7% (range, 19.7-42.6%) in 3 patients treated with a type V dialyzer (β2-microglobulin clearance ≥70 mL/min). In conclusion, our study showed that the VCM removal ratio varied according to type of dialyzer used and the dialysis vintage. Therefore, the administration should be designed individually in consideration of the differences in the dialyzer and dialysis conditions.

Key word

vancomycin, hemodialysis

Received

December 7, 2021

Accepted

June 10, 2022

Jpn. J. Chemother. 70 (5): 396-401, 2022